Journal of Clinical Psychopharmacology

There seems to be a reluctance to treat patients with medications that entail taking blood levels or dosage monitoring, extra patient education, attentiveness to interactions and side effects, or a step outside a comfort zone. Dr. Anthony Rothschild, our Editor-in-Chief, refers to this phenomenon as "psychopharmacologic laziness" and reviews possible remedies in a new Editorial and podcast. 🎧 Listen to the podcast: https://lnkd.in/eUTW8BtP 📰 Read the article: https://lnkd.in/egDvBbvN #psychopharmacology #lithium #clozapine #LAI #antipsychotics #therapeuticmonitoring #medicaleducation

Our November/December 2024 issue (Volume 44, issue 6) is now available. Access it online: https://lnkd.in/eJWvcUbb Brief synopsis of the new issue from the Journal of Clinical Psychopharmacology Editor-in-Chief is below.

According to the Centers for Disease Control and Prevention, products containing psychoactive compounds such as cannabis or mushroom extracts are increasing in availability and may contain undisclosed ingredients. Experts are warning about the increased incidence of acute illness and hospitalizations related to microdose psychoactive products. Tune in to our new podcast on this topic. 🎧 Listen to the podcast: https://lnkd.in/dQXQ8Xtu 📰 Read the article: https://lnkd.in/ed7vmtVH #psychopharmacology #psychoactive #adulterants #psychedelics #psilocybin #cannabis #LSD #microdosing #hospitalization #healthalert

Our upcoming issue features a new study on the effect of fluoxetine and sertraline on height growth and growth hormone signaling during puberty. Tune in to a new podcast by Dr. Chadi Calarge of Baylor College of Medicine for an overview of past and forward-looking research questions related to growth, growth hormones, and such drugs as selective serotonin reuptake inhibitors and stimulants. 🎧 Listen to podcast: https://lnkd.in/eHq289sA 📜 Read the article: https://lnkd.in/esP_WuCk #psychopharmacology #antidepressants #anxiolytics #SSRI #stimulants #fluoxetine #prozac #sertraline #zoloft #growthhormone #height #puberty

Think there’s nothing to worry about when it comes to #aripiprazole and the #QT interval? In our case report / lit review published today in Journal of Clinical Psychopharmacology, we (Dr Martin Osugo, Dr Antonio de Marvao, Prof Oliver Howes) describe a concerning increase in #QTc duration (from 420ms to 560ms!) in a healthy male taking aripiprazole 5-10mg daily as part of a #neuroimaging study 👇 https://lnkd.in/e5zJ_B2Z There are a few other reports of QT prolongation on aripiprazole; however, the link between drug and side-effect is clearest in our case - 1️⃣ our subject was a healthy volunteer on no other medication 2️⃣ ECGs at other time points were normal, as were blood tests, vital signs and clinical exams throughout the study 3️⃣ we collected plasma levels of drug and metabolite, so we *know* when the subject was and wasn’t taking the drug Finally - and perhaps most interestingly 🤔 - we sent the subject for clinical and genetic tests for #congenital #LQTS. Whilst most tests were normal, he was found to have a rare variant in one copy of the #Kv11.1 gene 🧬, which is thought to be a risk factor for QT prolongation under some conditions (such as certain drug exposure 💊 …) We call for a “thorough QT” (#TQT) study of aripiprazole, as has been undertaken for some other #antipsychotics (and many other non-#psychotropic medications). Until this is completed, we advocate closer ECG monitoring of patients on, or due to start, aripiprazole 🩺 UCL Division of Psychiatry Institute of Psychiatry, Psychology & Neuroscience MRC Laboratory of Medical Sciences (LMS) #psychiatry #psychopharmacology #neuropsychopharmacology

Voters will decide if Massachusetts becomes the third state to legalize certain psychedelics this November. Dr. Anthony Rothschild, the Editor-in-Chief of the Journal of Clinical Psychopharmacology, cautions against premature legislation while these medications are still being investigated in clinical trials. https://lnkd.in/eT7Yr3Z2

There are few reports of genitourinary side effects with atomoxetine. A new case report in JCP describes a case of painful ejaculation with this medication. While this side effect is rare, it could affect treatment adherence and necesitates psychoeducation and monitoring early in the course of treatment with atomoxetine for adult male patients. https://lnkd.in/eHZrdrKP #psychopharmacology #ADHD #atomoxetine #bupropion #nicotine #male #sexualdysfunction #painfulejaculation #genitourinary #adverseeffect #sideeffect #casereport

📢 The Journal of Clinical Psychopharmacology is announcing a call for papers to be published in 2025. Click here for information and instructions for submitting a manuscript: https://lnkd.in/dMYNdqFr

5-HT7 receptor blockade has been postulated to be a key component of cognitive enhancement in a number of drugs. A new study published in JCP evaluated the efficacy of JNJ-18038683, a 5-HT7 receptor antagonist, for improvement of cognitive impairment in bipolar disorder. https://lnkd.in/d2sDSMjz #psychopharmacology #serotonin #5HT #5HT7 #antagonism #JNJ18038683 #cognitivefunction #cognitiveimpairment #mooddisorder #bipolardisorder

A new randomized placebo-controlled trial shows that agomelatine, an atypical antidepressant that acts as an agonist of melatoninergic MT1/2 receptors and an antagonist of serotonergic 5-HT2C receptors, does not differentiate from placebo in its effect on the treatment of social anxiety. https://lnkd.in/etK9jFvb #psychopharmacology #agomelatine #melatoninergic #serotonergic #antidepressant #anxiety #socialanxiety